C4 Therapeutics (CCCC) Short term Debt (2022 - 2023)
C4 Therapeutics (CCCC) posted quarterly Short term Debt of $10.3 million for Q2 2023, up 1278.0% year-over-year from $750000.0 in Q2 2022, and up 351.9% quarter-over-quarter from $2.3 million in Q1 2023.
C4 Therapeutics (CCCC) Short term Debt (2022 - 2023) Analysis & Trends
C4 Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $10.3 million for Q2 2023.
- In Q2 2023, Short term Debt rose 1278.0% year-over-year to $10.3 million; the TTM figure through Jun 2023 stood at $10.3 million (up 1278.0% YoY), while the FY2022 annual figure was $2.3 million, changed N/A from the prior year.
- Short term Debt for Q2 2023 stood at $10.3 million, up from $2.3 million in the prior quarter.
- The five-year high for Short term Debt was $10.3 million in Q2 2023, with the low at $750000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |